GLP1R and chronic kidney disease: With the need to improve the cardiovascular profile of these patients, new classes of antidiabetic agents, including SGLT2is and GLP-1 RAs, have shown a significant reduction in cardiovascular and renal outcomes in patients with T2DM and CKD.